Enzyre, a spin-out from Radboud University Medical Centre in the Netherlands, has secured €12m in a Series A financing round to advance a diagnostic technology platform for haemophilia.

Led by new investor Oost NL, the funding round saw participation from the existing investors, Takeda Ventures, and Novalis Biotech, along with i&i Biotech Fund, and Demcon Investment as technology partners.

The Dutch Government has also offered to fund in the form of Innovation Credit.

Enzyre intends to use proceeds from the financing to further develop its diagnostic technology platform, EnzyPad.

EnzyPad platform is designed to determine and monitor the coagulation status of haemophilia patients in real time from their homes.

The funds will be used to support clinical trial registrations, open a sustainable manufacturing line, and invest in critical care setting applications.

Oost NL senior investment manager Pieter Rhemrev said: “We are excited to be working with Enzyre in developing a truly innovative technology that is a potential game changer in the management of Hemophilia A and other bleeding disorders.

“Patient outcomes and quality of life will be dramatically improved by the ability of physicians to monitor coagulation status in real-time and we see great potential for the product to enhance personalized care.

“We look forward to joining this talented team and our syndicate partners in supporting Enzyre’s pathway to future success.”

Haemophilia A is characterised by a lack of sufficient blood clotting factor VIII (FVIII) activity, which results in bleeding for prolonged times after an injury compared to healthy people.

Managing haemophilia involves complexities, and patients may benefit from safely monitoring the condition at home while staying connected with their care team.

Enzyre said that its technology will enable patients to self-test at home and send their coagulation status to the physician through a mobile app and a cloud-based application.

Its first product, Haemophilia EnzyCard, leverages the company’s EnzyPad platform technology to determine the coagulation status of patients with haemophilia.

The approach facilitates timely personalised therapy adjustments for improved clinical outcomes, while avoiding unnecessary travel and hospital exposure, said the company.

Enzyre chief executive officer Guido Maertens said: “We are delighted to have closed this successful financing round which validates our technology and will underpin our ongoing development as we take Enzyre forward into the next phase of growth.

“We value Takeda’s continued support and welcome the commitment from a strong cohort of new and existing investors.

“Together we look forward to improving the quality of life for patients living with bleeding disorders by driving forward our goal to transform their standard of care.”